241 related articles for article (PubMed ID: 32223021)
1. Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma.
Nagata A; Kanemasa Y; Sasaki Y; Nakamura S; Okuya T; Funasaka C; Kageyama A; Shimoyama T; Omuro Y
Hematol Oncol; 2020 Aug; 38(3):309-317. PubMed ID: 32223021
[TBL] [Abstract][Full Text] [Related]
2. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Go SI; Kim HG; Kang MH; Park S; Lee GW
BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
[TBL] [Abstract][Full Text] [Related]
3. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.
He J; Yin H; Xia Y; Wu JZ; Liang JH; Zhu HY; Fan L; Li JY; Wang L; Xu W
Leuk Res; 2021 Nov; 110():106664. PubMed ID: 34271293
[TBL] [Abstract][Full Text] [Related]
4. Is CONUT score a prognostic index in patients with diffuse large cell lymphoma?
Akgün Çağlıyan G; Hacıoğlu S; Ünver Koluman B; İlkkılıç K; Nar R; Başer MN; Bozdemir A; Şenol H; Şen Türk N; Erol V; Yılıdırım O; Çağlıyan Ö; Güler N
Turk J Med Sci; 2021 Aug; 51(4):2112-2119. PubMed ID: 33957727
[TBL] [Abstract][Full Text] [Related]
5. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.
Go SI; Park S; Kang MH; Kim HG; Kim HR; Lee GW
Ann Hematol; 2019 Feb; 98(2):401-411. PubMed ID: 30413902
[TBL] [Abstract][Full Text] [Related]
7. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
[TBL] [Abstract][Full Text] [Related]
8. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
9. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
[TBL] [Abstract][Full Text] [Related]
10. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
[TBL] [Abstract][Full Text] [Related]
12. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
[TBL] [Abstract][Full Text] [Related]
13. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
Lu CS; Chen JH; Huang TC; Wu YY; Chang PY; Dai MS; Chen YC; Ho CL
Leuk Lymphoma; 2015 Jul; 56(7):2047-55. PubMed ID: 25382616
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
16. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
18. Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma.
Matsukawa T; Suto K; Kanaya M; Izumiyama K; Minauchi K; Yoshida S; Oda H; Miyagishima T; Mori A; Ota S; Hashimoto D; Teshima T;
Ann Hematol; 2020 Dec; 99(12):2859-2868. PubMed ID: 32970194
[TBL] [Abstract][Full Text] [Related]
19. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
20. The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
Annibali O; Hohaus S; Marchesi F; Cantonetti M; Di Rocco A; Tomarchio V; Di Napoli A; Pelliccia S; Battistini R; Anticoli Borza P; Abruzzese E; Cenfra N; Andriani A; Tesei C; Alma E; Palombi F; Pupo L; Petrucci L; Becilli M; Maiolo E; Bellesi S; Cuccaro A; D'Alò F; Cox MC
Leuk Lymphoma; 2019 Dec; 60(14):3386-3394. PubMed ID: 31259651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
